US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ヨーロッパ
EU
Rolinco Robeco (ROLA) 銘柄情報

Rolinco Robeco (ROLA)

71.46

-0.05

(-0.07%)

終了 7月5日 12:30AM

Rolinco Robeco (ROLA) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

71.46

( -0.07% )

買値

71.51

売値

71.51

出来高

790

71.46 日の範囲 71.46

61.49 52 週間の範囲 74.51

時価総額

前日終値

71.51

始値

71.46

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

1,745 €

発行済株式数

12,668,549

配当利回り

0.8 (1.11%)

PER

106.64

1 株当たり利益 (EPS)

0.67

歳入

16.33M

純利益

8.84M

Rolinco N.V is an open-ended equity mutual fund launched and managed by Robeco Institutional Asset Management B.V. The fund invests in public equity markets of across the globe. It seeks to invest in stocks of companies operating across diversified sectors. The fund primarily invests in growth stock... Rolinco N.V is an open-ended equity mutual fund launched and managed by Robeco Institutional Asset Management B.V. The fund invests in public equity markets of across the globe. It seeks to invest in stocks of companies operating across diversified sectors. The fund primarily invests in growth stocks of companies. The fund benchmarks the performance of its portfolio against the MSCI All Country World Index. Rolinco N.V was formed on August 14, 2012 and is domiciled in Netherlands. 詳細を表示

セクター

-

業界

-

本社

Rotterdam, Netherlands

設立

2026

Rolinco Robeco is listed in the sector of the ユーロネクスト with ticker ROLA. The last closing price for Rolinco Robeco was 71.51 €. Over the last year, Rolinco Robeco shares have traded in a share price range of 61.49 € to 74.51 €.

Rolinco Robeco currently has 12,668,549 shares in issue. The market capitalisation of Rolinco Robeco is 905.29 € million. Rolinco Robeco has a price to earnings ratio (PE ratio) of 106.64.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	1.2	1.70794192997	70.26	71.55	70.26	1166	71.51514157	DE
4	0.38	0.53460889139	71.08	71.63	68.56	1629	70.84297862	DE
12	6.09	9.31620009179	65.37	74.51	65.37	1453	69.86890644	DE
26	3.43	5.04189328238	68.03	74.51	61.49	1613	68.44596022	DE
52	6.7	10.3458925263	64.76	74.51	61.49	1699	67.95331659	DE
156	16.33	29.6208960638	55.13	74.51	48.43	1942	62.7530629	DE
260	8.79	14.0258496888	62.67	74.51	45.79	1876	60.43330027	DE

ROLA - Frequently Asked Questions (FAQ)

What is the current Rolinco Robeco share price?

The current share price of Rolinco Robeco is 71.46 €

How many Rolinco Robeco shares are in issue?

Rolinco Robeco has 12,668,549 shares in issue

What is the market cap of Rolinco Robeco?

The market capitalisation of Rolinco Robeco is EUR 905.29M

What is the 1 year trading range for Rolinco Robeco share price?

Rolinco Robeco has traded in the range of 61.49 € to 74.51 € during the past year

What is the PE ratio of Rolinco Robeco?

The price to earnings ratio of Rolinco Robeco is 106.64

What is the cash to sales ratio of Rolinco Robeco?

The cash to sales ratio of Rolinco Robeco is 47.3

What is the registered address of Rolinco Robeco?

The registered address for Rolinco Robeco is Coolsingel 120, Rotterdam, Zuid-Holland, 3011 AG

gfp927z

gfp927z 45秒前

US Stablecoin consortium -

A huge development last week for the coming US national Stablecoin system. 140 of the biggest players in finance are forming a consortium to run and own the new US digital dollar / stablecoin system they call 'Open US' (links below). The stablecoin is lik

gfp927z

gfp927z 4分前

Bigworld, It looks like a huge development last week for the coming US national Stablecoin system. 140 of the biggest players in finance are forming a consortium to run and own the new US digital dollar / stablecoin system they call 'Open US' (links below). The stablecoin is like a CBDC (digital

Twiggs333

Twiggs333 25分前

GW Pharmaceuticals / Epidiolex is the pathway precedent people should be studying with respect to psychedelic biotech.

Jazz Pharmaceuticals acquired GW Pharmaceuticals for approximately $7.2 billion.

Why does that matter for psychedelic biotech?

Because G

Twiggs333

Twiggs333 25分前

GW Pharmaceuticals / Epidiolex is the pathway precedent people should be studying with respect to psychedelic biotech.

Jazz Pharmaceuticals acquired GW Pharmaceuticals for approximately $7.2 billion.

Why does that matter for psychedelic biotech?

Because G

Twiggs333

Twiggs333 26分前

GW Pharmaceuticals / Epidiolex is the pathway precedent people should be studying with respect to psychedelic biotech.

Jazz Pharmaceuticals acquired GW Pharmaceuticals for approximately $7.2 billion.

Why does that matter for psychedelic biotech?

Because G

Twiggs333

Twiggs333 26分前

GW Pharmaceuticals / Epidiolex is the pathway precedent people should be studying with respect to psychedelic biotech.

Jazz Pharmaceuticals acquired GW Pharmaceuticals for approximately $7.2 billion.

Why does that matter for psychedelic biotech?

Because G

OMOLIVES

OMOLIVES 30分前

Happy Fourth of July to all!...and a big thank you to the French. Vive la France!:

https://x.com/Phoenix2A_1980s/status/2073453266428387385

4u2nv2

4u2nv2 32分前

Every filing from the time Paul and Ben took over said there were 3 preferred shareholders. The third one was never named. Now, it's interesting to question how Newby got controlling interest when we do not know all of the facts concerning what Ben really wanted to accomplish with taking on the comm

Eli's Gone

Eli's Gone 43分前

I'm in: 11-5-24-19

Eli's Gone

Eli's Gone 44分前

gfp927z

gfp927z 45分前

>>> Look At Who Joined Open USD To Understand Where Money Is Going

Forbes

by Zennon Kapron

Jul 02, 2026

https://www.forbes.com/sites/digital-assets/2026/07/02/look-at-who-joined-open-usd-to-understand-where-money-is-going/

Sammy boy

Sammy boy 50分前

Said it 4 months ago Bessent is the problem ! There is a reason he cold-cocked Tommy Boy.

misterfishman

misterfishman 1時間前

Me too my side hobbies are researching new forms of energy from the enviroment,been at this for more than 20 yrs now and have accumilated a great deal oh knowledge.

Atlanta1

Atlanta1 1時間前

Joey - Why do you waste time on this lunatic?

FeMike

FeMike 1時間前

The original randomised primary endpoint (PFS) was negative and showed harm,

The simple fact that you don’t understand pseudo progression is more than enough to establish as also fact that you have no idea what you’re talking about.

1jas

1jas 1時間前

If you go to otcmarkets for AFFU news dated August 22 2023 it does mention AFFU and Dell partnership.

nyt

3 yrs down 79%. 5 yrs down 57%. 10 yrs down over 80%

gemstone57

gemstone57 1時間前

Happy Fourth of July guys we live in the greatest Nation on earth.

Tadaaa

Tadaaa 2時間前

johnydollar

johnydollar 2時間前

Have you ever wondered why clown fish like to hang out around the sea anemones........

😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆

GoodGuyBill

GoodGuyBill 2時間前

rcbindustry

rcbindustry 2時間前

I'm staying on the sidelines for now. Rocket Companies has potential over the long term, but I think the stock will continue to depend heavily on interest rates and the housing market. I'll be watching the next few quarters before becoming more optimistic.

Genz2

Genz2 2時間前

Now who would have thought of what Steven K Sprague came up with on X recently??? This country, Microsoft, Intel and Wave need Steven’s thinking!!!! If Steven’s court case is still in abeyance that is a real travesty!!! Steven is VERY UNIQUE in how he can masterfully come up with solutions that a

johnydollar

johnydollar 2時間前

You mean naked short enrichment right...........

😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 😹 😆 🤣 😂 Ƕ

Roman516

Roman516 2時間前

Happy 4th of July to all, GoodGuyBill, yes, I agree with you and your comment that "$35 billion is far too low for a treatment that will treat all tumor-based cancers (and we are not even discussing DIRECT, the combo patent, etc)."

If in fact, DCVax-D is able to address the majority o

Nanosphere Health Sciences (PK)

Wisdomtree India Ex stat...

Redeia Corporacion

Euronext Developed Asia ...

Southern Cross Gold Cons...

BetaShares Capital

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。